3-Nitropropionic acid induces a spectrum of Huntington's disease-like neuropathology in rat striatum

Neuropathology and Applied Neurobiology

Volumn 25, Issue 6, 1999, Pages 513-521

  Vis, J C ^a   Verbeek, M M ^b   De Waal, R M W ^b   Ten Donkelaar, H J ^b   Kremer, H P H ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

3 Nitropropionic acid; Huntington's disease; Neuropathology; Rat; Striatum

Indexed keywords

3 NITROPROPIONIC ACID; 4 AMINOBUTYRIC ACID; EOSIN; GLIAL FIBRILLARY ACIDIC PROTEIN; HEMATOXYLIN; SUBSTANCE P;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; MALE; NEUROPATHOLOGY; NEUROTOXICITY; NISSL STAINING; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; RAT;

ANIMALS; CORPUS STRIATUM; GAMMA-AMINOBUTYRIC ACID; GLIAL FIBRILLARY ACIDIC PROTEIN; HINDLIMB; HUNTINGTON DISEASE; IMMUNOHISTOCHEMISTRY; MALE; MOTOR ACTIVITY; NEURONS; NEUROTOXINS; NITRO COMPOUNDS; PROPIONIC ACIDS; RATS; RATS, WISTAR; SOMATOSTATIN; SUBSTANCE P;

EID: 0033379783     PISSN: 03051846     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2990.1999.00212.x     Document Type: Article

References (26)

1. 1 Alexi T, Hughes PE, Knüsel B, Tobin AJ. Metabolic compromise with systemic 3-nitropropionic acid produces striatal apoptosis in Sprague-Dawley rats but not in BALB/cByJ mice. Exp Neurol 1998; 153: 74-93
2. 2 Beal MF, Brouillet E, Jenkins BG et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 1993; 13: 4181-92
3. 3 Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 1992; 31: 119-30
4. 4 Benoit R, Ling N, Bakhit C, Morrison JH, Alford B, Guilemin R. Somatostatin-28 (1-12)-like immunoreactivity in the rat. Endocrinology 1982; 111: 1249-51
5. 5 Bossi SR, Simpson JR, Isacson O. Age dependence of striatal neuronal death caused by mitochondrial dysfunction. Neuroreport 1993; 4: 73-6
6. 6 Brennan Jr, Bird WA, Bird ED, Aprille JR. Regional mitochondrial respiratory activity in Huntington's disease brain. J Neurochem 1985; 44: 1948-50
7. 7 Brouillet E, Guyot MC, Mittoux V et al. Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat. J Neurochem 1998; 70: 794-05
8. 8 Dragunow M, Faull RLM, Lawlor P et al. In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes. Neuroreport 1995; 6: 1053-7
9. 9 Ellenbroek BA, Peeters BW, Honig WM, Cools AR. The paw test: a behavioural paradigm for differentiating between classical and atypical neuroleptic drugs. Psychopharmacology 1987; 93: 343-8
10. 10 Gerfen CR, Wilson CJ. The basal ganglia. In Handbook of Chemical Neuroanatomy, Integrated systems of the CNS, Part III, Vol. 12, Eds. LW Swanson, A Björklund, T Hökfelt. Amsterdam: Elsevier Science, 1996: 371-468
11. 11 Gould DH, Gustine DL. Basal ganglia degeneration, myelin alternations, and enzyme inhibition induced by the plant toxin 3-nitropropionic acid. Neuropathol Appl Neurobiol 1982; 8: 377-93
12. 12 Guyot MC, Hantraye P, Dolan R, Palfi S, Mazière M, Brouillet E. Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid. Neuroscience 1997; 97: 45-56
13. 13 Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosome. Cell 1993; 72: 971-83
14. 14 Isacson O, Sofroniew MV. Neuronal loss or replacement in the injured adult cerebral neocortex induces extensive remodelling of intrinsic and afferent neural systems. Exp Neurol 1992; 117: 151-75
15. 15 Kodsi MH, Swerdlow NR. Mitochondrial toxin 3-nitropropionic acid produces startle reflex abnormalities and striatal damage in rats that model some features of Huntington's disease. Neurosci Lett 1997; 231: 103-7
16. 16 Ludolph AC, Seeling M, Ludolph AG, Sabri MI, Spencer PS. ATP deficits and neuronal degeneration induced by 3-nitropropionic acid. Ann NY Acad Sci 1992; 648: 300-2
17. 17 Miller PJ, Zaborszky L. 3-Nitropropionic acid neurotoxicity: Visualization by silver staining and implications for use as an animal model of Huntington's disease. Exp Neurol 1997; 146: 212-29
18. 18 Nishino H, Kumazaki M, Fukuda A et al. Acute 3-nitropropionic acid intoxication induces striatal astrocytic cell death and dysfunction of the blood-brain barrier: involvement of dopamine toxicity. Neurosri Res 1997; 27: 343-55
19. 19 Nishino H, Shimano Y, Kumazaki M, Sakurai T. Chronically administered 3-nitropropionic acid induces striatal lesions attributed to dysfunction of the blood-brain barrier. Neurosci Lett 1995; 186: 161-4
20. 20 Novelli A, Reilly JA, Lysko PG, Henneberry RC. Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res 1988; 451: 205-12
21. 21 Portera-Cailliau C, Hedreen JC, Price DL, Koliatsos VE. Evidence of apoptotic cell death in Huntington disease and excitotoxic animal models. J Neurosci 1995; 15: 3775-87
22. 22 Thomas LB, Gates DJ, Richfield EK, O'Brien TF, Schweitzer JB, Steindler DA. DNA end labeling (TUNEL) in Huntington's disease and other neuropathological conditions. Exp Neurol 1995; 133: 265-72
23. 23 Vonsattel JPG, DiFiglia M. Huntington disease. J Neuropathol Exp Neuro 1998; 57: 369-84
24. 24 Vonsattel JPG, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985; 44: 559-77
25. 25 Wellington CL, Hayden R. Of molecular interactions, mice and mechanisms: new insights into Huntington's disease. Curr Opin Neurology 1997; 10: 291-8
26. 26 Wüllner U, Young AB, Penney JB, Beal MF. 3-Nitropropionic acid toxicity in the striatum. J Neurochem 1994; 63: 1772-81